Alvotech Snaps Up Xbrane’s R&D And Cimzia Rival For $27m
Swedish Biosimilars Developer Retains Ranibizumab And Nivolumab Assets
Sweden’s Xbrane has struck a deal to transfer its R&D operations in Sweden and its Cimzia (certolizumab pegol) biosimilar candidate to Alvotech, in a transaction worth around $27m. However, Xbrane told Generics Bulletin that it was not getting out of biosimilar development altogether.
